secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2026-06-29T10:30:58+00:00
Accession:  0001104659-26-078453
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma to be acquired by Zymeworks for $17.00/share cash plus CVR
-------------------------------------------------------------------------------

- Shareholders receive $17.00/share cash (~$929M equity value) plus a CVR for 80% of net proceeds from ampreloxetine monetization over ten years.
- Transaction represents a 22% premium to TBPH's March 3, 2026 close and 10% premium to VWAP since then.
- Merger expected to close in H2 2026, subject to shareholder vote (2/3 majority), HSR clearance, and customary conditions.
- Termination fees: $32.515M payable by either party under certain circumstances.
- Parent's debt financing commitment from OMERS Life Sciences; no financing condition for closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926078453/0001104659-26-078453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926078453/tm2619064d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-078453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer